On Tuesday, Predictive Oncology, Inc., announced it would be relocating its corporate headquarters to Pittsburgh, the location of its main laboratory facility.
Predictive Oncology is a science-driven company using artificial intelligence and machine learning to accelerate oncology drug discovery. The logistical initiative will strengthen the company’s commitment to scientific discovery and growth, officials said.
“This move reinforces the company’s commitment to growth, solidifying its footprint and expanding the laboratory and center for artificial intelligence in Pittsburgh,” Raymond F. Vennare, Predictive Oncology Chief Executive Officer and Chairman of the Board, said. “Our Company not only employs some of the world’s leading scientists in their respective fields, but has access to a critical mass of talent, many of whom were drawn to the region by Carnegie Mellon University, the University of Pittsburgh and UPMC Medical Center.”
The company recently expanded its facility to nearly 20,000 feet in the Lawrenceville section of Pittsburgh.
“Pittsburgh has long been a catalyst for innovation in the life sciences from Precision Therapeutics to the McGowen Institute for Regenerative Medicine and the Pittsburgh Tissue Engineering Initiative. Predictive Oncology stands on the shoulders of that kind of ingenuity and inventiveness,” Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery at Predictive Oncology, said. “With this move, our facility in Pittsburgh has now become the epicenter of our company’s artificial intelligence and clinical operations.”
Officials said the move puts the company closer to world-renowned universities and medical centers, as well as part of the next generation of Pittsburgh’s “innovation ecosystem.”